OWLT 10-K & 10-Q changes, risk factors and insider trading
Owlet, Inc. · NYSE · Measuring & Controlling Devices, Nec · CIK 1816708 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
New heading “We have a limited operating history at our current scale, which makes it difficult to evaluate our current business model and future prospects and may increase the risk of your investment.”
New heading “We currently rely on single-source contract manufacturers for the assembly of our sock monitor and camera products, and disruptions or cost increases could adversely affect our business.”
New heading “Gray market activity, product diversion, and theft could harm our brand, customer experience, and results of operations.”
New heading “Our reliance on NAND flash memory for our Dream Sight and Dream Duo product lines exposes us to significant supply shortages and cost volatility that could adversely affect our margins and product availability.”
New heading “We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could negatively affect our operating results, increase our costs and liabilities, require significant management attention, and adversely affect our financial condition and results of operations.”
New heading “We believe we will be required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act for our 2027 Annual Report on Form 10-K to be filed in early 2028. Failure to comply in a timely manner, or the identification of additional material weaknesses, could adversely affect our business and stock price.”
New heading “The market price of our common stock and warrants may be volatile. In addition, any trading market for our public warrants may be limited, and the market price of the public warrants (if any) may be more volatile and less liquid than the market for our common stock.”
Removed heading “We have a limited operating history.”
Removed heading “We currently rely on a single manufacturer for the assembly of our Dream Sock, Smart Sock and BabySat products and a single manufacturer for the assembly of our Owlet Cam. We will likely rely on single manufacturers for future products we may develop. If we encounter manufacturing problems or delays or increased costs, we may be unable to promptly transition to alternative manufacturers and our ability to generate revenue may be limited.”
Removed heading “Some of our products and services are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.”
Removed heading “If any governmental authority or notified body were to require marketing authorization or similar certification for any product that we sell for which we have not obtained such marketing authorization or certification, we could be subject to regulatory enforcement actions and/or be required to cease selling or recall the product pending receipt of marketing authorization or similar certification from such other governmental authority or notified body, which can be a lengthy and time-consuming process, harm financial results and have long-term negative effects on our operations.”
Removed heading “We are expanding into international markets, and we will be required to obtain and maintain regulatory authorizations, including clearances or approvals, or other certifications in order to commercialize certain of our products in certain international markets. Failure to obtain such regulatory authorizations or certifications in relevant foreign jurisdictions may prevent us from marketing medical device products abroad.”
Removed heading “Changing laws and increasingly complex corporate governance and public disclosure requirements could have an adverse effect on our business and operating results.”
Removed heading “Changes in the regulation of the internet could adversely affect our business.”
Removed heading “The price of our common stock and warrants may be volatile.”
Removed heading “We may acquire other businesses or form other joint ventures or make investments in other companies or technologies that could negatively affect our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.”
Removed heading “We may amend the terms of the warrants in a manner that may have an adverse effect on holders of public warrants with the approval by the holders of at least 50% of the then outstanding public warrants. As a result, the exercise price of your warrants could be increased, the exercise period could be shortened and the number of shares of common stock purchasable upon exercise of a warrant could be decreased, all without your approval.”
Removed heading “Our Warrant Agreement designates the courts of the State of New York or the U.S. District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of the warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with us.”
Largest changes
“We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions, which may increase our compliance costs and risk of enforcement, litigation, and reputational harm. …”see in full comparison
“We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the General Data Protection Regulation (“GDPR”) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the EEA, including in relation to use, collection, analysis, and transfer (including cross-border transfer) of such personal data. …”see in full comparison
“New and changing laws, regulations, and executive orders can adversely affect our business by increasing our costs, limiting the Company’s ability to pursue or offer a product candidate or product, and requiring changes to our business. New and changing laws, regulations, and executive orders can also create uncertainty about how such laws and regulations will be interpreted and applied. …”see in full comparison
Consequences of this indebtedness may require a substantial portion of cash flow from operations to be dedicated to the payment of principal and interest on our debt, thereby reducing our ability to use our cash flow to fund operations, capital expenditures, and future business opportunities. The interest rates on our indebtedness are variable and therefore we are exposed to changes in interest rates, which could materially impact our ability to make interest payments as well as our results of operations and financial condition. If we cannot generate sufficient cash flow from operations to service our debt, we may need to refinance our debt, dispose of assets or issue equity to obtain necessary funds. We do not know whether we would be able to take any of these actions on a timely basis, on terms satisfactory to us, or at all. A failure by us or our subsidiaries to comply with the agreements governing oursee in full comparisonindebtednessindebtedness, including the liquidity covenant under the ABL Credit Agreement could result in an event of default under suchindebtedness,indebtedness and its acceleration by the lenders, which could adversely affect our ability to respond to changes in our business and manage our operations. In addition, the ABL Credit Agreement contains a liquidity covenant requiring us to maintain liquidity of $4,000 and if the liquidity falls below $9,000, we are then subject to a minimum trailing-twelve-months EBITDA covenant as defined in the Credit Agreement. Upon the occurrence of an event of default under any of the agreements governing our indebtedness, the lenders could elect to declare all amounts outstanding to be due and payable and exercise other remedies as set forth in the agreements. If any of our indebtedness were to beaccelerated,accelerated and/or our lenders were to exercise other remedies, there can be no assurance that our assets would be sufficient torepaysatisfythistheindebtednessaccelerated obligations and any related amounts in full, which could have a material adverse effect on ourabilitybusiness,tofinancialcontinuecondition,toandoperateresultsasofa going concern.operations. As of December 31,2024,2025,$7.5$7.0 million in aggregate principal amount was outstanding in term loans under the Loan Facility Agreement and$6.3$6.9 million in aggregate principal amount was outstanding under the asset-based revolving credit facility under the ABL Credit Agreement. See Part II. Item 8. "Financial Statements and Supplementary Data - Note 7," included in this Report.
“We believe we will be required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act for our 2027 Annual Report on Form 10-K to be filed in early 2028. Failure to comply in a timely manner, or the identification of additional material weaknesses, could adversely affect our business and stock price.”see in full comparison
“Further, web and mobile browser developers, such as Apple, Microsoft or Google, have implemented and may continue to implement changes, including requiring additional user permissions, in their browser or device operating system that impair our ability to measure and improve the effectiveness of advertising of our products and services. …”see in full comparison
Full comparison: every changed paragraph (224)
Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business.business, some of which are described below. If any such risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. References to past events are provided by way of example only and are not intended to be a complete listing or representation as to whether or not such factors have occurred in the past or their likelihood of occurring in the future. The risk factors described below should be read together with the other information set forth in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission ("SEC").
We have a limited operating history at our current scale, which makes it difficult to evaluate our current business model and future prospects and may increase the risk of your investment.
We have a limited operating history.
We were organized in 2014 and began selling Owlet Smart Sock in 2015, Owlet Cam in 2018, launched Dream Sock in January 2022 and launched BabySat and Dream Sock with Health Notifications in 2024. We launched Owlet360, our first subscription service, and our Dream Sight camera in 2025. Additionally, as of December 31, 2025, had expanded our distribution and sale of Owlet products to include over 30 countries, with expansion into India and other countries expected in 2026. Accordingly, we have a limited operating history,history of offering multiple products, including software subscriptions, at our current scale, which makes anit evaluationdifficult ofto evaluate our current business model and future prospectsprospects. difficult.We Ourhave encountered and will continue to encounter risks and difficulties frequently experienced by growing companies in evolving industries. For example, our operating results have fluctuated in the past, and we expect our future quarterly and annual operating results to fluctuate as we focus on increasing the demand for our products and services. We may also experience challenges with accurate financial planning and forecasting. Additionally, we may need to make business decisions that could adversely affect our operating results, such as modifications to our pricing strategy, business structure or operations.operations, for a variety of reasons, including to achieve market acceptance of our existing and future product and service offerings, in response to competitive or macroeconomic pressures, or in the interests of driving long-term growth. We cannot assure you that we will be successful in addressing these and other challenges we may face in the future and if we do not manage these risks successfully, our business and operating results may be adversely affected. You should consider our business and prospects in light of the risks and difficulties we may encounter as we increase our product and service offerings and expand internationally.
We have nota beenhistory profitableof to date,losses and operatingmay not achieve or sustain profitability. Operating losses could continue, which could materially and adversely affect our business, financial condition and results of operations, including our ability to continue as a going concern.operations.
TheWe successhave a history of ourlosses businessand dependsmay onnot ourachieve abilityor tosustain increase revenues to offset expenses.profitability. Since our inception, we have incurred recurring operating losses, generated negative cash flows from operations, and financed our operations principally through equity raises and borrowings. During 2025, we incurred a net loss of $39.7 million and had an accumulated deficit of $307.9 million as of December 31, 2025. Future profitability is difficult to predict with certainty, and failure to achieve and sustain profitability could materially and adversely affect our overall value and ability to obtain additional financing and capital. There can be no assurance that the Companywe will generate sufficient future cash flows from operations due to various potential factors, including but not limited to inflation, recessionnegative macroeconomic conditions or decreased demand for our products. If our revenues decrease from current levels, we may be unable to further reduce costs, or such cost reductions may limit our ability to pursue and implement strategic initiatives and grow revenues in the future. Also,We theremay can be no assurance as to whether or when we will be able to obtainrequire additional debt or equity financing in the future, and such financing may not be available when needed, on acceptable terms.terms, or at all. Our ability to reduce operating expenses or raise capital from external sources, if at all, may have a material adverse effect on our business, financial condition and operating results. Those factors, coupled with our current cash balance and current debt obligations, raise substantial doubt as to our ability to continue as a going concern.
Prior to the Warning Letter, the Company experienced rapid revenue growth. Following a period of revenue decline subsequent to the Warning Letter, we have observed a significant recovery, with a 44.5% increase in revenue in 2024 compared to 2023 following receipt of marketing authorization for our BabySat and Dream Sock products. We anticipate that fluctuations in the growth of our business will continue as we adapt our plans and strategies to changing business and macroeconomic conditions.
Our business has experienced periods of significant fluctuations, including significant growth in revenue, headcount, our number of customers, usage, and amount of data delivered across our product offerings, since inception, which have placed, and we expect will continue to place, substantial demands on our management, financial, operational, and technological resources. For example, we experienced a 35.4% increase in revenue in 2025 compared to 2024 following receipt of marketing authorization for our BabySat and Dream Sock products. We anticipate that fluctuations in the growth of our business will continue as we adapt our plans and strategies to changing business and macroeconomic conditions. These fluctuations necessitate ongoing development and enhancement of our internal controls, including operational and financial systems. Any future growth initiatives will further intensify these demands:
In addition, we also expect to continue to incur additional legal, accounting, and other expenses as a public company. These investments may be more costly than we expect, and if we do not achieve the benefits anticipated from these investments, or if the realization of these benefits is delayed, they may not result in increased revenue or growth in our business. If we are not able to achieve or maintain positive cash flow in the long term, we may require additional financing, which may not be available on favorable terms or at all or which would be dilutive to our stockholders. If we are unable to successfully address these risks and challenges as we encounter them, our business, results of operations, and financial condition would be adversely affected. Our failure to achieve or maintain profitability could negatively impact the value of our common stock and warrants.securities.
We will likelymay need to raise additional capital in the future in order to executesupport our operations and strategic plan,plans, which may not be available to us when needed, on terms acceptable to us,terms, or at all.
We may need to raise additional capital in the future to support our operations and strategic plans. We have a history of losses from operations and negative cash flows from operations, and we may continue to incur operating losses.
We have experienced recurring losses from operations and negative cash flows from operations, and we expect to continue operating at a loss for the foreseeable future. As of December 31, 2024, we had an accumulated deficit of $268.2 million and cash and cash equivalents of $20.2 million. Our low, current cash balance, recurring operating losses, and negative cash flows from operations since inception raise substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued.
Our ability to raise capital as we have done in recent years may not always be successful, and we will likely need to raise additional capital to fund our future operations in order to remain as a going concern. There can be no assurance that we will be able to obtain additional funding on acceptable terms, if at all. To the extent that we raise additional capital through future equity offerings, the ownership interest of common stockholders will be diluted, which dilution may be significant. However, we cannot guarantee that we will be able to obtain any or sufficient additional funding or that such funding, if available, will be obtainable on terms satisfactory to us. Failure to secure additional funding may require us to modify, delay or abandon some of our planned future development, or to otherwise enact further operating cost reductions, which could have a material adverse effect on our business, operating results, financial condition and ability to achieve our intended business objectives.
Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock, and it may be more difficult for us to obtain financing. If potential investors decline to participate in any future financings due to such concerns, our ability to increase our cash position may be limited. The perception that we may not be able to continue as a going concern may cause others to choose not to deal with us due to concerns about our ability to meet our contractual obligations.
We have prepared our consolidated financial statements on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Our consolidated financial statements included in this Report do not include any adjustments to reflect the possible inability to continue as a going concern within one year after the date of the filing of this Annual Report on Form 10-K. If we are unable to continue as a going concern, you could lose all or part of your investment.
In addition, we have in the past and may in the future maintain our cash in bank deposit accounts which, at times, exceed federally insured limits. As of December 31, 2024, we maintain the majority of our cash and cash equivalents in accounts with primarily Silicon Valley Bank "SVB", a division of First Citizens Bank and Citibank, and exceeded federally insured limits. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position.
WeOur willability likelyto stillraise capital as we have done in recent years may not always be successful, and we may need additional funding to fund our operations,operations. butThere can be no assurance that we will be able to obtain additional funds may not be available to usfunding on acceptable terms on a timely basis, if at all. We may seek funds through borrowings or additional rounds of financing, including private or public equity or debt offerings, or by other means. Our future capital requirements will depend on many factors, including:
Consequences of this indebtedness may require a substantial portion of cash flow from operations to be dedicated to the payment of principal and interest on our debt, thereby reducing our ability to use our cash flow to fund operations, capital expenditures, and future business opportunities. The interest rates on our indebtedness are variable and therefore we are exposed to changes in interest rates, which could materially impact our ability to make interest payments as well as our results of operations and financial condition. If we cannot generate sufficient cash flow from operations to service our debt, we may need to refinance our debt, dispose of assets or issue equity to obtain necessary funds. We do not know whether we would be able to take any of these actions on a timely basis, on terms satisfactory to us, or at all. A failure by us or our subsidiaries to comply with the agreements governing our indebtednessindebtedness, including the liquidity covenant under the ABL Credit Agreement could result in an event of default under such indebtedness,indebtedness and its acceleration by the lenders, which could adversely affect our ability to respond to changes in our business and manage our operations. In addition, the ABL Credit Agreement contains a liquidity covenant requiring us to maintain liquidity of $4,000 and if the liquidity falls below $9,000, we are then subject to a minimum trailing-twelve-months EBITDA covenant as defined in the Credit Agreement. Upon the occurrence of an event of default under any of the agreements governing our indebtedness, the lenders could elect to declare all amounts outstanding to be due and payable and exercise other remedies as set forth in the agreements. If any of our indebtedness were to be accelerated,accelerated and/or our lenders were to exercise other remedies, there can be no assurance that our assets would be sufficient to repaysatisfy thisthe indebtednessaccelerated obligations and any related amounts in full, which could have a material adverse effect on our abilitybusiness, tofinancial continuecondition, toand operateresults asof a going concern.operations. As of December 31, 2024,2025, $7.5$7.0 million in aggregate principal amount was outstanding in term loans under the Loan Facility Agreement and $6.3$6.9 million in aggregate principal amount was outstanding under the asset-based revolving credit facility under the ABL Credit Agreement. See Part II. Item 8. "Financial Statements and Supplementary Data - Note 7," included in this Report.
Our products and services rely on our mobile applications to functionfunction, and we relydepend on Apple’s App Store and the Google Play Store for distributiondistribution, updates, and continued availability of our mobilethose applications.
Our products relyand subscription services are highly dependent on the installationcontinued availability and functionality of our mobile applications. If our mobile applications toare functionunavailable properly.or materially impaired, our camera products Dream Sight and Owlet Cam would be unusable, our Owlet360 subscription services would be unavailable, and Dream Sock functionality would be materially limited. Because our subscription services are delivered through our mobile applications, any disruption in service could adversely affect end customer acquisition, retention, and engagement. We develop mobile applications on Apple’s iOS platform and Google’s Android platform. Our customers download our mobile applications on Apple’s App Store and the Google Play Store. The App Store and Google Play Store are controlled entirely by Apple and Google, respectively. Mobile applications on the iOS platform are subject to approval by Apple and mobile applications on the Android platform are subject to approval by Google. The terms and policies for maintenance of existing applications and the approval process of new applications are very broad and subject to interpretationchange and frequentmay changes,be interpreted or applied in a manner adverse to us, and Apple and Google have complete control over the approval or removal of each mobile application submitted to or offered on their respective platforms. If either Apple or Google changes its standard terms and conditions for maintaining or approving mobile applications in a way that is detrimental to us or decide to remove our mobile applications from their stores, it will be much more difficult or may not be possible for users to install the mobile applications and receive updates to the mobile applications, and our current or future products may cease to function as intended.intended or at all. In addition, changes in iOS, Android, app store requirements, or third-party APIs could require us to modify our applications, could introduce performance issues, and could delay or prevent the release of updates or new features. Apple has informed us that it will remove our mobile applications from the App Store in any country in which any Owlet product requires marketing authorization or certification from any governmental authority or notified body. Any such removal or suspension could occur with limited advance notice and could be difficult to remedy quickly If Apple removes our applications from the App Store or Google removes our applications from the Google Play Store, our products would not function as intended,intended or at all, and we may be required to recall our products, issue refunds and accept returns, and we may be subject to costly litigation.litigation, and our business, financial condition and results of operations could be materially affected.
Historically, we have relied on a limited number of retailers for a substantial portion of our total sales. For example, sales through our topthree threelargest customers represented 58%66.5% of our revenue for the year ended December 31, 20242025 and 54%63.0% for the year ended December 31, 2023.2024. These retailers work with us on a non-exclusive basis. If we are unable to establish, maintain or grow these relationships over time, or if these relationships grow more slowly than we anticipate, we are likely to fail to recover these costs and our operating results will suffer. The loss of any significant retail customer, whether or not related to our business or our products or services, could have an impact on the growth rate of our revenue as we work to obtain new retail customers or replacement relationships. In addition, retailers may reduce purchases, change product assortment, reduce shelf or online placement, delay, cancel, or return orders, or discontinue carrying our products with limited advance notice. Contracts with retailers may typically be terminated or renegotiated before their term expires for various reasons, subject to certain conditions. For example, after a specified period, certain of our contracts are terminable for convenience by such retailers, subject to a notice period. Additionally, certain contracts may be terminated immediately by the retailer if we go bankrupt or if we fail to comply with certain specified laws. Any renegotiation of the commercial agreements may result in less favorable economic terms for us. Retailers may also seek price concessions, increased promotional funding, cooperative marketing support, or other allowances, or impose or increase chargebacks, credits, or return rights, any of which could adversely affect our margins and operating results. Retailers may also consolidate their operations, reducing the overall number of locations in which they sell our products and services. Ongoing challenges affecting brick-and-mortar retail, including store closures, reduced foot traffic, and shifts in consumer purchasing behavior toward e-commerce, may reduce demand for our products through these channels and could cause retailers to reduce orders, limit in-store placement, or increase promotional activity and pricing pressure. Historically, we have had retail customers declare bankruptcy and stop operations, negatively affecting our sales and business. If regulatory actions such as the Warning Letter we received in October 2021 regarding the regulatory status of the Smart Sock are threatened or taken against us or our products, or if we are required to modify, suspend, or withdraw any products or product features, retailers may return and stop carrying and return our products. Such returns have had, and may have,have a material adverse effect on our business, financial condition and results of operations.
In order to grow our business, we anticipate that we will continue to depend on our relationships with third parties, including our retailers. IdentifyingCompetition retailers,for retail distribution is significant, and negotiating and documenting relationships with them, requires significant time and resources. Ourour competitors may be more effective in providingsecuring incentivesfavorable toplacement, thirdpromotional parties to favor their productssupport, or services.other commercial terms. If we are unsuccessful in establishing, or maintainingmaintaining, or strengthening our relationships with third parties, including our retailers, our ability to compete in the marketplace or to grow our revenue could be impaired and our results of operations may suffer. Even if we are successful, these relationships may not result in increased customer use of our services or increased revenue.
We currently rely on single-source contract manufacturers for the assembly of our sock monitor and camera products, and disruptions or cost increases could adversely affect our business.
We currently rely on a single manufacturer for the assembly of our Dream Sock, Smart Sock and BabySat products and a single manufacturer for the assembly of our Owlet Cam. We will likely rely on single manufacturers for future products we may develop. If we encounter manufacturing problems or delays or increased costs, we may be unable to promptly transition to alternative manufacturers and our ability to generate revenue may be limited.
We have no manufacturing capabilities of our own. We currently rely on a single manufacturer located in Thailand, Benchmark Electronics, for the manufacture of our Dream Sock, Smart Sock and BabySat products. Additionally, we currently rely on a separate single manufacturer located in China,China Shenzhenand AoniVietnam, Electronic,Aoni, for the manufacture of ourDream Owlet Cam.Sight. We expect to rely on limited manufacturers for future products we may develop. For us to be successful, our contract manufacturers must be able to provide us with products in substantial quantities, in compliance with regulatory requirements, in accordance with agreed upon specifications, at acceptable costs and on a timely basis. Our existing manufacturers may not be able to continue to meet our demand requirements on a timely basis, and their ability and willingness to continue to do so going forward may be limitedaffected forby severala reasons,number of factors, including our relative importance as a customer of each manufacturermanufacturer, capacity constraints, and disruptions to their operations or theirthose respectiveof abilitykey tosuppliers. provideOur assemblyoperations, servicesand tothose manufactureof our products,contract whichmanufacturers and key suppliers, may be adversely affected by pandemicsnatural disasters or other naturalcatastrophic or man-made disasters. Earthquakes are of particular significance since our headquarters are located in an earthquake-prone area. We are also vulnerable to damage from other types of disasters,events, including earthquakes, power loss, attackscyber fromincidents, extremistepidemics or terroristpandemics, organizations,fires, epidemics,floods, severe weather, acts of terrorism, geopolitical instability, communication failures, fire, floods and similar events. Certain of these events may be exacerbated by climate change; for more information, (see our risk factor titled “—We are subject to a series of risks regarding climate change.”). Furthermore, weWe are also subject to the risk that one or more of our critical third-party manufacturers,manufacturers may experience financial instability, file for bankruptcy, or otherwise cease operations.operations, The loss of a key providerwhich could result in significant supply chain delays, inability to meet sales demand, and increased costs associated with transitioning to alternative providers. In addition, componentComponent parts sourcedand frommaterials theseused suppliersin our products may also be subject to tariffs or other limitations imposed by the U.S. administration, which could limit availability of necessary parts for our products, increase our costs and impact our business and results of operations (see “—Increases in tariffs, trade restrictions or taxes on our products could have an adverse impact on our operations.”). Furthermore,In addition, our manufacturing agreements can be terminated by our contract manufacturers without cause by giving us prior notice of six months or less. The facilities and the manufacturing equipment used to produce our products would be difficult to replace and could require substantial time to repair if significant damage were to result from any of these occurrences. An interruption in our commercial operations could occur if we encounter delays or difficulties in securing these manufactured products for any reason and we cannot obtain an acceptable substitute.
Gray market activity, product diversion, and theft could harm our brand, customer experience, and results of operations.
We sell our products through a combination of retailers, distributors, and direct-to-consumer channels, and we rely on third parties for storage, fulfillment, and transportation of our products. We may be subject to product theft, loss, diversion, or unauthorized resale, including through online marketplaces. In addition, as we expand internationally and operate across multiple distribution channels, we may experience increased “gray market” activity, including the unauthorized import, export, resale, or diversion of our products outside authorized distribution channels.
Products that are stolen, diverted, or sold through unauthorized channels may be offered at discounted prices that disrupt our pricing strategy, reduce demand through authorized channels, and strain relationships with retailers and other channel partners. Such products may be marketed with inaccurate or unauthorized claims, may not include labeling, instructions, warnings, software versions, or other materials applicable to the jurisdiction where they are ultimately sold, and may not be eligible for warranty coverage, customer support, software updates, or other services associated with products sold through authorized channels. As a result, customer complaints and returns may increase, and we may incur additional costs to monitor, investigate, and pursue enforcement actions against unauthorized sellers, including through civil litigation or marketplace takedown processes.
Unauthorized resale and diversion can also increase the risk that counterfeit, altered, refurbished, or improperly handled products are attributed to us, which could harm our reputation and brand, result in negative publicity, and expose us to product liability claims and regulatory scrutiny, including if products are sold in jurisdictions where different regulatory requirements apply. If we are unable to prevent, detect, or effectively respond to product theft, diversion, or unauthorized resale, our business, financial condition, and results of operations could be materially and adversely affected.
Our reliance on NAND flash memory for our Dream Sight and Dream Duo product lines exposes us to significant supply shortages and cost volatility that could adversely affect our margins and product availability.
We rely on NAND flash memory components for our Dream Sight and Dream Duo products to provide local video storage, buffer high-resolution video streams, and host device firmware. The global semiconductor market is currently experiencing a structural shortage of NAND flash as major suppliers (such as Samsung, SK Hynix, and Micron) prioritize capital expenditure for High-Bandwidth Memory (HBM) and Enterprise-grade Solid State Drives (SSDs) to meet the demand for AI infrastructure.
This memory shortage and the resulting market dynamics pose several risks to our business:
•Supply Concentration and Strategic De-prioritization: Because NAND manufacturers have shifted production capacity toward higher-margin enterprise and data center applications, supply for consumer-grade NAND flash memory has tightened significantly. We may face difficulty securing sufficient allocations to meet our production forecasts for the Dream Sight and Dream Duo lines.
•Significant Cost Increases: As of early 2026, contract prices for NAND flash memory have increased significantly. Any inability to lock in long-term pricing at favorable rates could significantly increase our component costs and reduce our gross margins. We may be unable to pass these increased costs on to consumers in a competitive retail environment.
•Inventory and Cash Flow Risks: To mitigate the risk of production halts, we may elect to engage in "pre-buying" or enter into long-term purchase commitments for NAND flash memory components. Such actions could increase our inventory carrying costs, negatively impact our liquidity, and expose us to the risk of future write-downs if market prices decline or if our product demand forecasts prove inaccurate.
•Impact on Product Roadmap: A prolonged NAND flash memory shortage could delay the launch of future generations of our Dream Duo or Dream Sight products, particularly those requiring higher storage capacities or faster write speeds to support advanced imaging features.
If we are unable to manage these supply chain disruptions effectively, or if our suppliers further prioritize enterprise customers over consumer electronics original equipment manufacturers, our ability to fulfill customer orders will be impaired, which would negatively impact our business, results of operations and financial condition.
Because our products and services are used by caregivers to monitor infants, it is critical that our products and services be accessible without interruption or degradation of performance. Customers may become dissatisfied by any system failure that interrupts our ability to provide our services to them. Sustained or repeated system failures would reduce the attractiveness of our products or services to customers. Moreover, negative publicity arising from these types of disruptions could damage our reputation and may adversely impact use of our products and services.services and our ability to attract and retain customers.
We currently host our products and services, serve our customers and support our operations primarily from third-party data and call centers and other cloud-based services. For example, we rely on cloud services and bespoke software services provided by Ayla Networks for our Dream Sock and Smart Sock products to support the transfer of data to the cloud and back to us and the user. Additionally, we rely on the data transfer services of ThroughTek to enable video viewing access for the Owlet Cam.Cam and Dream Sight. We do not have control over the operations of the services or the facilities of any of those providers. These facilities are vulnerable to damage or interruption from earthquakes, hurricanes, floods, fires, cyber security attacks, terrorist attacks, power losses, telecommunications failures and similar events. Certain of these events may be exacerbated by climate change; for more information, (see our risk factor titled “—We are subject to a series of risks regarding climate change.”). The occurrence of a natural disaster or an act of terrorism, a decision by a provider to close theor discontinue facilities or services without adequate notice, or other unanticipated problems could result in lengthy interruptions in our services. The facilities also could be subject to break-ins, computer viruses, sabotage, intentional acts of vandalism and other misconduct. We may not be able to easily switch our cloud operations to another cloud provider ifon thereacceptable areterms, disruptionswithin a reasonable timeframe, or interferencewithout withservice suchinterruption, providers.including due to technical, contractual, or operational constraints.
Furthermore, we are subject to the risk that one or more of our critical third-party providers, such as Ayla Networks or ThroughTek, may experience financial instability, file for bankruptcy, or otherwise cease operations. The loss of a key provider could result in significant disruptions to our services, delays in product functionality, and increased costs associated with transitioning to alternative providers. BecauseGiven the nature of our products areand essential for infant monitoring,services, any such disruption could severely damage our reputation and adversely affect our business, financial condition, and results of operations.
We are highly dependent on our senior management, other key officers, our engineers, marketing and field sales team, and may be increasingly dependent on healthcare and clinical specialists for the sale of any medical devices we may market. We face significant competition for talent from other healthcare, technology and high-growth companies, which include both large enterprises and privately-held companies. To attract top talent, we have had to offer, and believe we will need to continue to offer, highly competitive compensation packages (including equity-based compensation) and to incur recruiting and onboarding costs before we can validatefully theevaluate productivityan ofemployee's those employees.performance. In addition, we may not be able to hire new employees quickly enough to meet our needs or effectively integrate new hires, and fluctuations in the price of our common stock may make it more difficult or costly to use equity compensation to motivate, incentivize and retain our employees.
In addition, we recruit professionals on a global basis and must comply with the immigration laws in the countries in which we operate, including the U.S. Some of our employees are working under Owlet-sponsored temporary work visas, including H1-B visas. Statutory law limits the number of new H1-B temporary work permit petitions that may be approved in a fiscal year. Furthermore, there is a possibility that the current administration of the U.S. immigration visa program mayis beundergoing significant change, including a significantly overhauled,increased H1-B visa fee and changes in the number ofway H1-B visas available,are asawarded. well as the process to obtain them, may be subject to significant change. Any resultingThese changes to this visa program could impact our ability to recruit, hire and retain qualified skilled personnel. If we are unable to obtain work visas in sufficient quantities or at a sufficient rate for a significant period of time, our business, operating results and financial condition could be adversely affected.
Some of our products and services are in development or have been recently introduced into the market and may not achieve market acceptance, which could limit our growth and adversely affect our business, financial condition and results of operations.
Our portfolio of products and services continues to expand, and we are investing significant resources to enter into, and in some cases create, new markets for these products and services. We are continuing to invest in sales and marketing resources to achieve market acceptance of these products and services, but our technologies may not achieve general market acceptance. New products and services, such as BabySat or our subscription offering, Owlet360, may also fail to achieve the market acceptance that we anticipate.
The degree of market acceptance of these products and services will depend on a number of factors, including:
•perceived benefits from and safety of our products and services;
•perceived cost effectiveness of our products and services;
•our ability to obtain any required marketing authorizations or certifications for our products and services and the label requirements of any marketing authorizations or certifications we may obtain;
•coverage and reimbursement available through government and private healthcare programs for using some of our products and services; and
•introduction and acceptance of competing products and services or technologies.
If our products and services do not gain market acceptance or if our customers prefer our competitors’ products and services, our potential revenue growth would be limited, which would adversely affect our business, financial condition and results of operations.
If we are unable to successfully developdevelop, introduce, and effectivelydrive manage the introductionadoption of new productsproducts, services, and services,enhancements, our businessbusiness, mayfinancial condition and results of operations could be adversely affected.
Our portfolio of products and services continues to expand, and we invest significant time and resources to develop, introduce, and drive adoption of new products, services, and software-enabled enhancements, including by investing in sales, marketing and support resources and, as applicable, obtaining required regulatory authorizations or certifications. If we are unable to successfully develop and effectively manage the introduction of these offerings on a timely basis, or if they do not perform as intended, achieve market acceptance, or meet customer expectations, our growth may be limited and our business, financial condition, and results of operations could be adversely affected.
Market acceptance of our products and services depends on a number of factors, including perceived benefits and safety,perceived cost effectiveness, our ability to obtain and maintain required marketing authorizations or certifications (and any related labeling limitations), coverage and reimbursement dynamics for products used in healthcare settings, and the introduction and acceptance of competing products, services or technologies. In addition, the introduction or announcement of newer products, services or enhancements may reduce demand for, or shorten the lifecycle of, our existing products and services.
We may also experience operational and financial challenges associated with product and service introductions. Development and commercialization efforts can be time-consuming and costly, may require specialized hiring and training, and may involve manufacturing and supply chain complexity, including potentially higher costs for regulated products or products subject to evolving regulatory requirements, which could adversely affect our gross margins. If demand for our products and services is lower than we forecast, we may experience excess inventory, increased promotional activity, and inventory write-downs or write-offs. Conversely, if demand is higher than we forecast, we may incur increased shipping costs, including expedited freight, to meet customer expectations, and our results of operations could become more volatile. We have experienced inventory management challenges in the past and may experience similar challenges in the future.
If we fail to effectively develop, introduce and manage adoption of new products, services and enhancements, or if customers prefer competing offerings, our revenue growth could be limited and our business, financial condition and results of operations could be materially adversely affected.
We must successfully manage introductions of new or advanced products, such as BabySat and Dream Sock, and services, such as the development of our software platform and our subscription offering, Owlet360. Development of new products and services requires the expenditure of considerable time and resources, but we may not be able to successfully develop and introduce such products on a timely basis, or at all. Products and services that are not well-received by the market may lead to excess inventory and discounting of our existing products and services. Inventory levels in excess of consumer demand may result in inventory write-downs or write-offs and the sale of inventory at discounted prices, may affect our gross margin and could impair the strength of our brand. Reserves and write-downs for rebates, promotions and excess inventory are recorded based on our forecast of future demand. Actual future demand could be less than our forecast, which may result in additional reserves and write-downs in the future, or actual demand could be stronger than our forecast, which may result in increased shipping costs and a reduction to previously recorded reserves and write-downs in the future and increase the volatility of our operating results.
Introductions of new or advanced products and services could also adversely impact the sales of our existing products and services to consumers. For instance, the introduction or announcement of new or advanced products and services may shorten the life cycle of our existing products or reduce demand, thereby reducing any benefits of successful product or service introductions and potentially leading to challenges in managing write-downs or write-offs of inventory of existing products and services. In addition, some of our products are regulated by the FDA and foreign regulatory agencies as medical devices and require marketing authorization from the FDA and similar marketing authorization or certification from other applicable regulatory authorities or notified bodies prior to commercialization. New products, particularly those products needing to meet FDA or other regulatory requirements, may have higher manufacturing costs than legacy products, which could negatively impact our gross margins and operating results. Accordingly, if we fail to effectively manage introductions of new or advanced products and services, our business may be adversely affected.
We have in the past experienced challenges managing the inventory of our products, which has led and may in the future lead to increased shipping costs for air freight in order to fulfill customer orders in a timely manner, which has affected our gross margin and could impair the strength of our brand.
We face and expect to face increasing competition from other companies, many of which have substantially greater resources than we do. If we do not successfully develop and commercialize enhanced or newinnovative products and services that remain competitive with products and services or alternative technologies developed by others,competitive, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired, adversely affecting our financial condition and results of operations.
Management's Discussion & Analysis (MD&A)
New heading “Equity Financings”
New heading “Debt and Other Financing Arrangements”
Removed heading “Dream Sock De Novo Device Classification”
Removed heading “NYSE Notification”
Removed heading “SVB Revolver and Term Loan”
Removed heading “Emerging Growth Company Status”
Largest changes
“The Credit Agreement contains representations, warranties, covenants, and events of default customary for agreements of this type. OBCI's obligations under the Credit Agreement are: (i) fully and unconditionally guaranteed by Owlet, Inc.; and (ii) secured by a security interest in substantially all our personal property assets, including Owlet Inc.'s pledge of the outstanding capital stock of the Company. Among these covenants is a liquidity covenant requiring the Company to maintain liquidity of $4,000. …”see in full comparison
“Adjusted EBITDA is defined as net loss adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets related to internally developed software, common stock warrant liability adjustments, stock-based compensation, transaction costs, charges related to certain legal matters, and restructuring costs.”see in full comparison
We have included a certain non-GAAP financial measure in this Annual Report, adjusted EBITDA. Adjusted EBITDA is defined as net loss adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets, common stock warrant liability adjustment, stock-based compensation, transaction costs, charges related to certain legal matters, net of insurance loss recovery related to certain legal matters, and restructuring costs. We usesee in full comparisonsuchthis non-GAAP financialmeasuresmeasure as an internalmeasuresmeasure of business operating performance and as performance measures for benchmarking against our peers and competitors. We believe our presentation of adjusted EBITDA provides a meaningful perspective of the underlying operating performance of our current business and enables investors to better understand and evaluate our historical and prospective operating performance. We believe that this non-GAAP financial measure is an important supplemental measure of operating performance because it excludes items that vary from period to period without correlation to our core operating performance and highlight trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures. Due to the nature of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. We believe investors, analysts and other interested parties use adjusted EBITDA in evaluating issuers, and the presentation of these measures facilitates a comparative assessment of our operating performance in addition to our performance based on GAAP results.
“The WTI Loan Facility contains certain reporting and operational covenants that we must meet in order to borrow funds under the Loan Commitments and not cause an event of default. Upon the occurrence of an event of default, WTI could elect to force redemption of the outstanding balances under the WTI Loan Facility, requiring us to pay all outstanding principal and accrued interest, as well as all scheduled unpaid interest on the loan, including PIK interest. Upon the occurrence of an event of default, we will also be required to pay default interest on any overdue balances at a rate of 5.0%. …”see in full comparison
“We fund our operations primarily with proceeds from issuances of our equity securities, borrowings under our loan facilities, and sales of our products and services. As of December 31, 2025, we had cash and cash equivalents of $35,461, and additional availability of $9,897 on our line of credit. We believe our existing cash and cash equivalent balances, cash flows from operations, and committed credit lines will be sufficient to meet our long-term working capital and capital expenditure needs for at least the next 12 months. …”see in full comparison
“In April 2023, we were notified by NYSE that we were not in compliance with Section 802.01B of the NYSE Listed Company Manual as the average global market capitalization of our common stock over a consecutive 30 trading-day period and, at the same time, our last reported stockholders’ equity were each less than $50,000 (the “NYSE Notification”). …”see in full comparison
Full comparison: every changed paragraph (106)
Owlet is a leading pediatric health platform and the only company globally to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors for home use. By delivering hospital-grade technology through a consumer-friendly interface, we bridge the critical gap between clinical care and the home.
Dream Sock De Novo Device Classification
Our Dream Sock has received a de novo device classification from United States Food and Drug Administration (“FDA”) for a first-of-its kind, over-the-counter device for use in the home environment that provides a notification to the caregiver when an infant’s pulse rate and/or oxygen saturation moves outside of preset ranges (“Health Notifications”), displays the infant’s live pulse rate and oxygen saturation values and trends (“Live Health Readings”), and is intended for use in infants who are 1 to 18 months of age and between 6 and 30 pounds.
NYSE Notification
In April 2023, we were notified by NYSE that we were not in compliance with Section 802.01B of the NYSE Listed Company Manual as the average global market capitalization of our common stock over a consecutive 30 trading-day period and, at the same time, our last reported stockholders’ equity were each less than $50,000 (the “NYSE Notification”). In May 2023, we submitted a business plan advising the NYSE of the definitive actions we had taken as of the date of that submission and were planning on taking in order to bring us into compliance with NYSE continued listing standards within 18 months of receipt of the NYSE Notification. The plan was accepted by the NYSE in July 2023. On October 10, 2024, we received formal notice from the NYSE that we had regained compliance with the NYSE’s continued listing standards. As a result of our achievement of compliance with the NYSE’s minimum market capitalization requirement for the requisite period of time, the NYSE has advised us that we are no longer considered out of compliance with these continued listing standards, and the below compliance “BC” indicator has been removed from our Class A common stock (“common stock”). Additionally, we are no longer noted as being below continued listing standards on the NYSE’s website (www.nyse.com). In accordance with the NYSE’s Listed Company Manual, we will be subject to a 12-month follow-up period within which we will be reviewed to confirm that we do not once again fall below any of the NYSE’s continued listing standards. There can be no assurance that we will be able to maintain compliance with these or any other NYSE listing requirements during or after the 12-month follow-up period. See Part I, Item 1A. “Risk Factors—Our failure to meet the NYSE’s continued listing requirements could result in a delisting of our common stock” in this Report.
We recognize revenue primarily from products and the associated mobile applications. Revenues are recognized when control of goods and services is transferred to customers in an amount that reflects the consideration expected to be received by us in exchange for those goods and services. Substantially all of our revenues were derived from product sales.sales, with a growing minority portion of revenues being generated from subscriptions to our Owlet360 service.
Cost of revenues consists of product costs, including contract manufacturing, shipping and handling, depreciation and amortization relating to tooling and manufacturing equipment and software, warranty replacement, fulfillment costs, warehousing, hosting and platform costs, and reserves for excess and obsolete inventory. Cost of revenues associated with Owlet360 mainly consist of app store distribution fees.
General and Administrative. General and administrative expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for finance and accounting, legal, human resources, operations, quality and administrative executives and employees; third-party legal, accounting, customer service, software, and other professional services; corporate travel and entertainment; depreciation and amortization of property and equipment, asset impairment charges, legallitigation settlements,settlement costs, insurance loss recovery, and facilities rent.
Research and Development. Research and development expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for employees and contractors engaged in the design, development, maintenance, and testing of our productsproducts, platforms and platforms,services, including quality and clinical testing.
Interest Income (Expense), Net. Interest income (expense), net consists of interest incurred on our outstanding borrowings, debt extinguishment costs, gain on interest for forgiveness of interest accrued related to an arrangement with a significant vendor,borrowings and amortization of the associated deferreddebt financing costs. Interest income consists of interest earned on our money market account.funds and other cash and cash equivalents.
Other Income (Expense), Net. Other income (expense), net includes our net gain (loss) on foreign exchange transactions.transactions and transaction costs.
The increase was primarily due to higher sales of Dream Sock and Dream Duo products, reflecting an increase in consumer demand as compared to the prior year. To a lesser extent, growth in revenue generated from subscriptions to our Owlet360 service, which launched in January 2025, also contributed to the increase.
Revenues increased by $24,046, or 44.5%, from $54,010 for the year ended December 31, 2023 to $78,056 for the year ended December 31, 2024. The increase was primarily due to higher sales of Dream Sock products, reflecting an increase in consumer demand across all sales channels as compared to the prior year.
The increase in cost of revenues was primarily due to the increase in product sales. The increase in gross margin was primarily due to higher revenue, favorable product mix, improved fixed cost absorption, and lower direct product and fulfillment costs. To a lesser extent, the increase in gross margin was also attributed to the growth in revenue from subscriptions to our Owlet360 service. These contributions to gross margin expansion were partially offset by the impact of tariffs, which was more pronounced during the second half of 2025.
Cost of revenues increased by $7,325, or 23.3%, from $31,423 for the year ended December 31, 2023 to $38,748 for the year ended December 31, 2024. The increase was primarily due to the increase in product sales. Gross margin increased from 41.8% for the year ended December 31, 2023 to 50.4% for the year ended December 31, 2024 primarily due to higher revenue, favorable product mix, lower returns, improved fixed cost absorption, and lower direct product and fulfillment costs.
The decrease was driven primarily by the absence of significant litigation settlement costs and impairment charges recognized in 2024, which did not recur in the current period, and lower severance expenses. The decrease was partially offset by increases in headcount related expenses, including salaries, bonus, and benefits, as well as increased stock-based compensation, driven by a notable increase in our common stock price during 2025.
General and administrative expense increased by $6,624, or 24.2%, from $27,343 for the year ended December 31, 2023 to $33,967 for the year ended December 31, 2024. The increase was driven primarily by litigation settlements, impairment charges related to intangible assets, and higher compensation expense, including accrued bonuses and severance-related expenses. These increases were partially offset by reduced insurance premiums, less bad debt expense, and lower consulting and outside services spend related to transaction costs as compared to the prior year.
The increase was driven primarily by higher marketing expenses and increases in headcount related expenses, including salaries, commissions, bonus, and benefits.
Sales and marketing expense increased by $2,233, or 16.5%, from $13,527 for the year ended December 31, 2023 to $15,760 for the year ended December 31, 2024. The increase was driven primarily by higher compensation expense due to additional employees, higher commissions from higher sales, and accrued bonuses, along with higher spend on social media marketing and public relations as compared to the prior year.
The increase was driven primarily by increased investment in research and development, particularly with product development, quality, and clinical testing, and increases in headcount related expenses, including salaries, bonus, and benefits.
Research and development expense decreased by $548, or 5.3%, from $10,349 for the year ended December 31, 2023 to $9,801 for the year ended December 31, 2024. The decrease was driven primarily by lower stock-based compensation expense and higher costs capitalized related to internal-use software, partially offset by accrued bonuses as compared to the prior year.
The increase in interest expense was driven primarily by interest and amortization of debt financing costs related to our current term loan facility and asset-based revolving credit facility, which were entered into in September 2024, as well as the absence of a gain on interest for forgiveness of interest accrued related to an arrangement with a significant vendor that was fully settled in September 2024, partially offset by the absence of termination fees related to the SVB term loan that was terminated in September 2024.
Fluctuations in our common stock warrant liability adjustment resulted from an increase in our common stock price, and the related increase in the fair value of liability-classified common stock warrants. As described further in Note 9, most of these common stock warrants were exchanged for common shares in October 2025.
Changes in other income (expense) were driven primarily by transaction costs related to the Warrant Exchange as discussed in Note 9. Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock, within the Notes to Consolidated Financial Statements included elsewhere in this Report.
Interest expense decreased by $1,561, from $3,191 for the year ended December 31, 2023 to $1,630 for the year ended December 31, 2024. During the year ended December 31, 2023, we entered into an agreement with a significant vendor to pay $3,000 of interest over 36 months with respect to past due payables. The present value of the future payments was expensed and included within interest expense, net on the consolidated statements of operations in that period. In January 2024, the agreement was amended and the schedule of interest payments was modified from 36 months to 28 months, but the amount of interest payable was unchanged. In September 2024, the agreement was amended again, allowing us to terminate the agreement with a final interest payment of $623, which was then fully settled in September 2024. The reduction in the total cumulative interest payments to $2,206 resulted in us recording a reduction of interest expense at termination of $508. The decrease in interest expense for the year ended December 31, 2024 was partially offset by interest related to the Company's term loan facility and asset-based revolving credit facility, which were entered into in September 2024.
For the year ended December 31, 2024, we recognized a gain of $9,293 as compared to a loss of $924 for the same period in the prior year resulting from a decrease in the fair value of common stock warrants outstanding.
We have included a certain non-GAAP financial measure in this Annual Report, adjusted EBITDA. Adjusted EBITDA is defined as net loss adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets, common stock warrant liability adjustment, stock-based compensation, transaction costs, charges related to certain legal matters, net of insurance loss recovery related to certain legal matters, and restructuring costs. We use suchthis non-GAAP financial measuresmeasure as an internal measuresmeasure of business operating performance and as performance measures for benchmarking against our peers and competitors. We believe our presentation of adjusted EBITDA provides a meaningful perspective of the underlying operating performance of our current business and enables investors to better understand and evaluate our historical and prospective operating performance. We believe that this non-GAAP financial measure is an important supplemental measure of operating performance because it excludes items that vary from period to period without correlation to our core operating performance and highlight trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures. Due to the nature of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. We believe investors, analysts and other interested parties use adjusted EBITDA in evaluating issuers, and the presentation of these measures facilitates a comparative assessment of our operating performance in addition to our performance based on GAAP results.
OurAdjusted non-GAAP financial measuresEBITDA should not be considered as an alternative to net loss as a measure of financial performance or any other performance measure derived in accordance with GAAP,GAAP and should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.
Adjusted EBITDA is defined as net loss adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets related to internally developed software, common stock warrant liability adjustments, stock-based compensation, transaction costs, charges related to certain legal matters, and restructuring costs.
Adjusted EBITDA is not a recognized termsterm under GAAP, and our presentation of this non-GAAP measuresmeasure does not replace the presentation of our financial results in accordance with GAAP. Because all companies do not use adjusted EBITDA (and similarly titled financial measures) in the same way, those measures as used by other companies may not be consistent with the way we calculate such measures. The non-GAAP financial measure included in this report should not be construed as a substitute for or better indicators of the Company’s performance than the most directly comparable GAAP financial measures. See the reconciliation tablestable below for additional information regarding the non-GAAP financial measure included herein (in thousands):
We fund our operations primarily with proceeds from issuances of our equity securities, borrowings under our loan facilities, and sales of our products and services. As of December 31, 2025, we had cash and cash equivalents of $35,461, and additional availability of $9,897 on our line of credit. We believe our existing cash and cash equivalent balances, cash flows from operations, and committed credit lines will be sufficient to meet our long-term working capital and capital expenditure needs for at least the next 12 months. Our future capital requirements may vary materially from those currently planned and will depend on many factors, including our rate of revenue growth, the timing and extent of spending on research and development efforts and other business initiatives, our planned sales and marketing activities, the timing of new product introductions, market acceptance of our products, and overall economic conditions. To the extent that current and anticipated sources of liquidity are insufficient to fund our future business activities and requirements, we may be required to seek additional equity or debt financing. The sale of additional equity would result in increased dilution to our stockholders. If we were to incur additional debt financing, it would result in increased debt service obligations and the instruments governing such debt could require additional operating and financing covenants that would restrict our operations.
Tariffs announced in 2025 have adversely impacted our cost of goods sold and gross margins and may continue to affect cash flows if elevated tariff rates persist.
Equity Financings
Refer to Note 9 within the Notes to Consolidated Financial Statements included elsewhere in this Report for additional details regarding our common stock issuance, redeemable common stock, common stock warrants, and convertible preferred stock.
On August 7, 2025, we entered into a privately negotiated Exchange Agreement with certain Holders of our Series A Warrants and Series B Warrants, in which the Holders agreed to exchange with us their Series A Warrants relating to an aggregate of 7,215,737 shares of common stock and, if applicable, their Series B Warrants relating to an aggregate of 1,799,021 shares of common stock, for an aggregate of 5,426,429 of newly issued shares of common stock. We consummated the Exchanges and the issuance of the Exchange Shares on October 10, 2025. See Note 9. Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock, within the Notes to Consolidated Financial Statements included elsewhere in this Report, for additional details regarding this agreement.
On October 23, 2025, we completed an underwritten public offering in which we issued and sold 4,196,000 shares of our common stock at a price of $7.15 per share. Subsequently, the underwriters exercised their over-allotment option for an additional 629,400 shares, which settled after the initial closing and increased the total shares issued in the offering to 4,825,400. From this offering, we received net proceeds of $32,109 after deducting underwriting discounts and commissions.
Debt and Other Financing Arrangements
Refer to Note 6 within the Notes to Consolidated Financial Statements included elsewhere in this Report for additional details regarding our debt arrangements, including the expected maturity of such arrangements.
We fund our operations primarily with proceeds from issuances of our convertible preferred stock, issuances of our common stock, borrowings under our loan facilities, issuances of convertible promissory notes, and sales of our products and services. As of December 31, 2024, we had cash and cash equivalents of $20,245.
On February 17, 2023 we entered into private placement investment agreements with certain investors, pursuant to which we issued and sold to the investors (i) an aggregate of 30,000 shares of our Series A convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 7,871,712 shares of our common stock, par value $0.0001 per share (“February 2023 Warrants”) for an aggregate purchase price of $30,000.
The Series A convertible preferred stock is convertible into common stock at the option of the holder at any time after February 17, 2023 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) senior to the common stock and all other classes or series of our equity securities established after February 17, 2023, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (ii) on parity with each class or series of our equity securities established after February 17, 2023, the terms of which expressly provide that it ranks on parity with the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iii) junior to each class or series of our equity securities established after February 17, 2023, the terms of which expressly provide that it ranks senior to the Series A convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. On August 20, 2024, holders of the Series A Preferred Stock elected to convert an aggregate of 15,721 shares of Series A Preferred Stock in exchange for an aggregate of 2,291,686 shares of common stock. Except as otherwise provided in the certificate of designation relating to the Series A convertible preferred stock or as required by law, holders of shares of Series A convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of our stockholders, and not as a separate class.
At any time from and after February 17, 2028, the holders of at least a majority of the then outstanding shares of Series A convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series A preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 145.7726 per share (the "Conversion Rate"), (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series A preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.
Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, we will be required to pay an amount per share of Series A Preferred Stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series A Preferred Stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series A Preferred Stock.
Each of the February 2023 Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $4.66 per share, is immediately exercisable, and will expire on February 17, 2028. None of the warrants have been exercised as of December 31, 2024. As the February 2023 Warrants could require cash settlement in certain scenarios, the warrants were classified as liabilities upon issuance and were initially recorded at an aggregate estimated fair value of $26,133. The total proceeds from the offering were first allocated to the liability classified warrants, based on their fair values, with the residual $3,867 allocated to the Series A convertible preferred stock. The Series A convertible stock will accrete to their redemption value, starting from the issuance date to the date at which the shares become redeemable on February 17, 2028. Accretion will be recorded as a deemed dividend.
We incurred $1,963 of issuance costs related to the offering, of which $1,513 were paid as of December 31, 2023. The remaining $450 were paid as of December 31, 2024. Issuance costs allocated to the preferred stock of $253 were recorded as a reduction to the Series A preferred stock. Issuance costs allocated to the liability classified warrants of $1,710 were recorded as an expense within general and administrative expenses.
On February 25, 2024 we entered into a private placement investment agreement with certain investors, pursuant to which we issued and sold to the investors (i) an aggregate of 9,250 shares of our Series B convertible preferred stock, par value $0.0001 per share and (ii) warrants to purchase an aggregate of 1,799,021 shares of our common stock, par value $0.0001 per share (the “February 2024 Warrants”), for an aggregate purchase price of $9,250.
The Series B convertible preferred stock is convertible into common stock at the option of the holder at any time after February 29, 2024 and ranks, with respect to dividend rights, rights of redemption and rights upon a liquidation event, (i) equal to our Series A convertible preferred stock, (ii) senior to the common stock and all other classes or series of our equity securities established after February 29, 2024, unless such shares or equity securities expressly provide that they rank in parity with or senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption or rights upon a liquidation event, (iii) on parity with each class or series of our equity securities established after February 29, 2024, the terms of which expressly provide that it ranks on parity with the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event and (iv) junior to each class or series of our equity securities established after February 29, 2024, the terms of which expressly provide that it ranks senior to the Series B convertible preferred stock with respect to dividend rights, rights of redemption and rights upon a liquidation event. Except as otherwise provided in the certificate of designation relating to the Series B convertible preferred stock or as required by law, holders of shares of Series B convertible preferred stock are entitled to vote with the holders of shares of common stock (and any other class or series that may similarly be entitled to vote with the holders of common stock) on an as-converted to common stock basis at any annual or special meeting of our stockholders, and not as a separate class.
At any time from and after March 1, 2029, the holders of at least a majority of the then outstanding shares of Series B convertible preferred stock may specify a date and time or the occurrence of an event by vote or written consent that all, and not less than all, of the outstanding shares of Series B preferred stock will automatically be: (i) converted into shares of common stock at a conversion rate of 129.6596 per share, (ii) subject to certain exceptions and limitations, redeemed for an amount per share of Series B preferred stock equal to the liquidation preference of one thousand dollars per share, plus all accrued or declared but unpaid dividends as of the redemption date and time or (iii) a combination of the foregoing.
Subject to certain exceptions, upon the occurrence of a fundamental change, voluntary or involuntary liquidation, dissolution or winding-up of the Company, we will be required to pay an amount per share of Series B Preferred Stock equal to the greater of (i) one thousand dollars per share or (ii) the consideration per share of Series B Preferred Stock as would have been payable had all such shares been converted to common stock immediately prior to the liquidation event, plus, in each case, the aggregate amount of all declared but unpaid dividends thereon to the date of final distribution to the holders of Series B preferred stock.
Each of the February 2024 Warrants sold in the private placement offering is exercisable for one share of common stock at an exercise price of $7.7125 per share, is immediately exercisable, and will expire on March 1, 2029. None of the warrants have been exercised as of the filing of this Annual Report on Form 10-K.
The Company incurred $394 of issuance costs related to the offering. Issuance costs allocated to the preferred stock of $102 were recorded as a reduction to the Series B convertible preferred stock. Issuance costs allocated to the liability classified warrants of $292 were recorded as an expense within general and administrative expenses on the consolidated statements of operations.
On September 11, 2024, we entered into the underwriting agreement and issued 3,135,136 shares of our common stock at a price to the public of $3.70 per share, less underwriting discounts and commissions. The net proceeds we received were $10,590. In addition, we incurred $874 in issuance costs, of which $286 was issuance costs that were unpaid as of December 31, 2024. We provided the underwriter a discount of 7% off the offering price. In addition to the underwriter discount, the offering expenses with third parties were $874, of which $286 in issuance costs that were unpaid as of December 31, 2024. We also reimbursed the underwriters for $198 in fees and expenses, including legal expenses, out-of-pocket expenses, and clearing expenses. The issuance costs associated with the September 2024 Offering were recorded as a reduction to additional paid-in capital on the consolidated balance sheets.
Pursuant to the underwriting agreement, we also issued, as a portion of the underwriting compensation payable to the underwriter, a warrant to purchase up to 125,405 shares of our common stock (which was subsequently transferred to certain affiliates of the underwriter, the “Titan Warrants”). The Titan Warrants are initially exercisable on March 13, 2025 at an exercise price of $4.63 and have a term of five years from such initial exercise date.
SVB Revolver and Term Loan
On November 23, 2022, we entered into the Third Amended and Restated Loan and Security Agreement (as amended, the “LSA”) with Silicon Valley Bank, a division of First Citizens Bank and Trust Company (“SVB”). The LSA provided for a $10,000 revolving line of credit (the “SVB Revolver”) and for an $8,500 term loan, which amortized with equal monthly installments of $500.
On September 11, 2024, we terminated the LSA with SVB and used existing cash to prepay and extinguish all borrowings outstanding under the line of credit and term loan facilities with SVB. In addition to normal principal and interest, we paid $761 of termination fees to extinguish the loan. Of the total termination fees recorded, during the year ended December 31, 2024, $407 was recorded as interest expense, net on the consolidated statements of operations, and $11 was recorded within general and administrative expense on the consolidated statements of operations. The remaining $343 was accrued as interest expense, net, in prior periods.
As of December 31, 2025 principal outstanding on the loan was $7,012. The net carrying value of the WTI Loan Facility was $5,609, which includes the outstanding principal and accrued PIK interest of $249, net of $1,652 in unamortized debt financing costs.
As of December 31, 2025, we were in compliance with all covenants under the WTI Loan Facility.
On September 11, 2024 (the “Effective Date”), we, as guarantor, and our wholly-owned subsidiary, Owlet Baby Care, Inc., a Delaware corporation (“OBCI,” and together with us, collectively, the “Loan Parties”), as the borrower, entered into a Loan Facility Agreement (the “Loan Facility Agreement”) with WTI Fund X, Inc. and WTI Fund XI, Inc. (collectively “WTI” for a term loan facility of up to $15,000 (the “WTI Loan Facility”).
The WTI Loan Facility consists of two tranches. The first tranche of $10,000 was available at closing and through September 30, 2024, with $2,500 of the first tranche availability extendable until December 31, 2024 (the “First Tranche Commitment”). OBCI initiated our first drawdown under the WTI Loan Facility of $7,500 (the “Initial Loan”) shortly after closing. WTI and OBCI agreed to extend the remaining $2,500 of the First Tranche Commitment to March 31, 2025. As of the filing date, OBCI has not drawn on the remaining $2,500. Once repaid, we cannot reborrow from the WTI Loan Facility.
What changed in the latest 10-Q
Risk Factors
In addition to the information contained in this Report, you should carefully consider the risk factors described in our Form 10-K and Form 10-K/A, which are incorporated herein by reference, which could materially affect our business, financial condition or results. There have been no material changes to the risk factors described in our Form 10-K and Form 10-K/A.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
New heading “Wells Fargo Line of Credit”
Largest changes
“On June 26, 2026, we entered into a 3-year $25,000 secured asset-based revolving credit agreement with Wells Fargo Bank, National Association (“Revolving Facility”) that includes a $10,000 accordion feature under which the Revolving Facility may be expanded by agreement of the parties from up to $25,000 to up to $35,000 (in minimum increments of at least $5,000). …”see in full comparison
“Tariffs announced in 2025 have adversely impacted our cost of goods sold and gross margins and may continue to affect cash flows if elevated tariff rates persist. On February 20, 2026, the U.S. Supreme Court issued a decision invalidating tariffs imposed under IEEPA. This ruling could result in tariff relief and may allow for the recovery of amounts previously paid, which we believe could be material. We are currently evaluating the potential effects of this decision on our financial condition and liquidity. …”see in full comparison
“Tariffs announced in 2025 have adversely impacted our cost of goods sold and gross margins and may continue to affect cash flows if elevated tariff rates persist. In February 2026, the U.S. Supreme Court issued a ruling invalidating certain tariffs previously imposed under the International Emergency Economic Powers Act (IEEPA). As a result of this ruling, we were eligible for a refund of tariffs previously paid on imported goods. During the three months ended June 30, 2026, we received $3,960 in IEEPA tariff refunds. …”see in full comparison
“In addition, from time to time, our operating expenses include restructuring costs. Restructuring costs in the periods presented primarily related to employee severance in connection with our CEO transition in April 2026 and, to a lesser extent, management-approved plans designed to improve our cost structure and/or operations, such as our previously-announced decision to exit lower-margin, high-burden revenue streams in non-core geographies and new channels. …”see in full comparison
“The increase for the six months ended June 30, 2026 was driven primarily by approximately $2,700 of stock-based compensation, a substantial portion of which was associated with the CEO transition in April 2026, approximately $700 in increases of headcount related expenses, including salaries and benefits, and approximately $600 in restructuring costs related to our CEO transition in April 2026 and previously-announced reprioritization of core geographies and revenue channels with the remainder attributable to other normal course of business items.”see in full comparison
Full comparison: every changed paragraph (48)
The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Report and in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Form 10-K and Form 10-K/A. Certain statements we make under the following discussion and analysis constitute “forward-looking statements” under the Reform Act. See “Cautionary Note Regarding Forward-Looking Statements” in this Report. You should consider our forward-looking statements in light of the risks discussed in our unaudited condensed consolidated financial statements, related notes and other financial information appearing elsewhere in this Report, the section entitled “Risk Factors” in our Form 10-K, Form 10-K/A and this Report, and our other filings with the SEC. Note that amounts included in the following discussion and analysis are presented in thousands and may not sum due to rounding. Also note that reported amounts reflect the revisions discussed in Note 11 to the consolidated financial statements as applicable.
Cost of revenue consists of product costs, including contract manufacturing, shipping and handling, depreciation and amortization relating to tooling and manufacturing equipment and capitalized internally developed software, warranty replacement, fulfillment costs, warehousing, hosting and platform costs, and reserves for excess and obsolete inventory. Cost of revenue associated with Owlet360 mainly consists of app store distribution fees.fees and amortization relating to capitalized internally developed software.
General and Administrative. General and administrative expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for finance and accounting, legal, human resources, operations, quality and administrative executives and employees; third-party legal, accounting, customer service, software, and other professional services; corporate travel and entertainment; depreciation and amortization of property and equipment, asset impairment charges, litigation settlement costs, insurance loss recovery, and facilities rent.
Research and Development. Research and development expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for employees and contractors engaged in the design, development, maintenance, and testing of our products, platforms and services, including quality and clinical testing. In addition, research and development expenses that qualify as internal-use software development costs are capitalized, reducing the expenses software development costs incurred in the period, and the amount capitalized may fluctuate significantly from period to period.
In addition, from time to time, our operating expenses include restructuring costs. Restructuring costs in the periods presented primarily related to employee severance in connection with our CEO transition in April 2026 and, to a lesser extent, management-approved plans designed to improve our cost structure and/or operations, such as our previously-announced decision to exit lower-margin, high-burden revenue streams in non-core geographies and new channels. Restructuring expenses consist of employee severance costs, contract termination costs and certain other exit costs to improve our cost structure in the future.
Other Income (Expense), Net. Other income (expense), net includes our net gain (loss) on foreign exchange transactionstransactions, net gain (loss) on insurance claim proceeds, and transactioninterest costs.income on tariff refunds.
Loss on debt extinguishment. Excess of the reacquisition price paid to settle debt over its net carrying value.
The decreaseincrease in hardware revenue for the three months ended June 30, 2026 was primarily due to approximately $3,100$6,800 impact fromreflecting aan largeincrease retailin partnerconsumer tightening weeks of supply on handdemand as well as timing differences of load-inscompared to retailers,the prior year, partially offset by approximately $1,800$1,300 decreaseincrease in retail discounts due to the timing of promotion load-in dates, and approximatelyreturns $400associated increasedwith direct-to-consumerhigher demand.sales volume.
The increase in subscription revenue for the three months ended June 30, 2026 was due to an increase in subscribers for our Owlet360 service and higher average revenue per user.
The increase in hardware revenue for the six months ended June 30, 2026 was driven by an approximately $4,300 increase attributable to higher consumer demand compared to the prior year period, partially offset by an approximately $200 increase in discounts and returns resulting from the timing of promotional load-in dates and higher sales volume.
The increase in subscription revenue for the six months ended June 30, 2026 was due to an increase in subscribers for our Owlet360 service and higher average revenue per user.
The decrease in hardware cost of revenue for the three months ended June 30, 2026 was primarily due to the decreaseimpact of tariff refunds, partially offset by an increase in product sales. The decreaseincrease in hardware gross margin was primarily due to the impact of tariffs,tariff partially offset byrefunds, favorable product mixmix, and lowerfavorable directfixed productcost and fulfillment costs.absorption.
The increase in subscription cost of revenue for the three months ended June 30, 2026 was primarily due to increased subscriptions to our Owlet360 service. The increasedecrease in subscription gross margin is attributable to efficiencieshigher gainedapp duestore todistribution a larger subscription base.fees.
The decrease in hardware cost of revenue for the six months ended June 30, 2026 was primarily due to the impact of tariff refunds, partially offset by an increase in product sales. The increase in hardware gross margin was primarily due to the impact of tariff refunds, favorable product mix, and favorable fixed cost absorption.
The increase in subscription cost of revenue for the six months ended June 30, 2026 was primarily due to increased subscriptions to our Owlet360 service. The decrease in subscription gross margin is attributable to higher app store distribution fees.
The increase for the three months ended June 30, 2026 was driven primarily by approximately $1,400 of stock-based compensation, a substantial portion of which was associated with the CEO transition in April 2026, approximately $600 in restructuring costs related to our CEO transition in April 2026 and the previously-announced reprioritization of core geographies and revenue channels, approximately $200 in bad debt expense with the remainder attributable to other normal course of business items.
The increase for the six months ended June 30, 2026 was driven primarily by approximately $2,700 of stock-based compensation, a substantial portion of which was associated with the CEO transition in April 2026, approximately $700 in increases of headcount related expenses, including salaries and benefits, and approximately $600 in restructuring costs related to our CEO transition in April 2026 and previously-announced reprioritization of core geographies and revenue channels with the remainder attributable to other normal course of business items.
The increase was driven primarily by approximately $1,400 of stock-based compensation, and by approximately $800 in increases of headcount related expenses, including salaries and benefits.
The increase for the three months ended June 30, 2026 was driven primarily by approximately $300 in higher marketing personnel and consulting costs, $200$1,500 in expanded retail marketing spend,spend due to a shift in timing of large promotional event from the third quarter to the second quarter 2025, and approximately $100 in increased stock-based compensation, partially offset by $100 in miscellaneous net decreases.compensation.
The increase for the six months ended June 30, 2026 was driven primarily by approximately $1,700 in expanded retail marketing spend due to a shift in timing of large promotional event from the third quarter to the second quarter, and approximately $200 in increased stock-based compensation.
The increase for the three months ended June 30, 2026 was driven primarily by approximately $800$1,100 in higher personnel costs, $400approximately $300 in stock-based compensation, and $200approximately $100 in regulatoryrestructuring testingcosts andrelated geographicthe expansionpreviously-announced costs.reprioritization of core geographies. These increases were partially offset primarily by approximately $300$700 decrease due to decreased regulatory testing and geographic expansion costs and an increase in increasedcapitalized capitalizedinternally developed software costs.
The increase for the six months ended June 30, 2026 was driven primarily by approximately $1,900 in higher personnel costs, approximately $700 in stock-based compensation, and approximately $100 in restructuring costs related the previously-announced reprioritization of core geographies. These increases were partially offset primarily by approximately $800 decrease due to decreased regulatory testing and geographic expansion costs and an increase in capitalized internally developed software costs.
*Not meaningful ("NM").
The decrease in interest expense for the three and six months ended June 30, 2026 was driven primarily by a decrease in loan commitment amortization related to ourthe currentWTI term loan facility due to the last loan commitment period ending in November 2025.
Fluctuations in our common stock warrant liability adjustment resultedfor fromthe three and six months ended June 30, 2026 represents a decreasesignificantly inreduced ourmagnitude commonof stock price, and the related decrease in theperiod-over-period fair value remeasurement of liability-classified common stock warrants.warrants as a result of the October 2025 warrant exchange.
Changes in other income (expense) for the three and six months ended June 30, 2026 were driven primarily by a gaingains from insurance proceeds.proceeds and interest income related to tariff refunds.
Loss on debt extinguishment for the three and six months ended June 30, 2026 was due to the extinguishment of the WTI term loan facility and ABL Line of Credit, of which $1,472 was due to the write-off of unamortized debt financing costs and unamortized loan commitment assets previously capitalized on the unaudited condensed consolidated balance sheets.
Adjusted EBITDA is defined as net income (loss) adjusted for income tax provision, interest expense, net, depreciation and amortization, impairment of intangible assets, common stock warrant liability adjustment, stock-based compensation, and charges related to certain legal matters.matters, restructuring costs, and loss on debt extinguishment.
We fund our operations primarily with proceeds from issuances of our equity securities, borrowings under our loan facilities,facility, and sales of our products and services. As of MarchJune 31,30, 2026, we had cash and cash equivalents of $35,459,$30,948, and additional availability of $3,944$7,531 on our line of credit. We believe our existing cash and cash equivalent balances, cash flows from operations, and committedborrowing capacity under our asset-based revolving credit linesagreement will be sufficient to meet our long-term working capital and capital expenditure needs for at least the next 12 months. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis and accordingly, do not include any adjustments relating to the recoverability and classification of asset carrying amounts, or the amount and classification of liabilities that might result should we be unable to continue as a going concern. There can be no assurance that we will generate sufficient future cash flows from operations due to potential factors, including but not limited to inflation, recession, or reduced demand for our products. If revenue decreases from current levels, we may be unable to further reduce costs, or such reductions may limit our ability to pursue strategic initiatives and grow revenue in the future. Our future capital requirements may vary materially from those currently planned and will depend on many factors, including our rate of revenue growth, the timing and extent of spending on research and development efforts and other business initiatives, our planned sales and marketing activities, the timing of new product introductions, market acceptance of our products, and overall economic conditions. To the extent that current and anticipated sources of liquidity are insufficient to fund our future business activities and requirements, we may be required to seek additional equity or debt financing. The sale of additional equity would result in increased dilution to our stockholders. If we were to incur additional debt financing, it would result in increased debt service obligations and the instruments governing such debt could require additional operating and financing covenants that would restrict our operations.
Tariffs announced in 2025 have adversely impacted our cost of goods sold and gross margins and may continue to affect cash flows if elevated tariff rates persist. In February 2026, the U.S. Supreme Court issued a ruling invalidating certain tariffs previously imposed under the International Emergency Economic Powers Act (IEEPA). As a result of this ruling, we were eligible for a refund of tariffs previously paid on imported goods. During the three months ended June 30, 2026, we received $3,960 in IEEPA tariff refunds. Of this amount, $3,526 was recorded as a reduction to cost of goods sold for inventory sold, $205 was recorded as a reduction in the carrying value of inventory, and $229 was recorded as a component of other income (expense), net on the unaudited condensed consolidated statement of operations and comprehensive income (loss). The scope, duration, and impact of future tariff policies remain uncertain and could adversely affect our business, financial condition, results of operations, and cash flows. We will continue to monitor developments in this area and take actions to mitigate potential impacts as appropriate.
Tariffs announced in 2025 have adversely impacted our cost of goods sold and gross margins and may continue to affect cash flows if elevated tariff rates persist. On February 20, 2026, the U.S. Supreme Court issued a decision invalidating tariffs imposed under IEEPA. This ruling could result in tariff relief and may allow for the recovery of amounts previously paid, which we believe could be material. We are currently evaluating the potential effects of this decision on our financial condition and liquidity. The process for recovering previously paid duties/tariffs remains subject to ongoing proceedings with the U.S. Court of International Trade and U.S. Customs and Border Protection. We are actively monitoring these developments and are taking steps to preserve our rights with respect to any potential refunds.
Wells Fargo Line of Credit
On June 26, 2026, we entered into a 3-year $25,000 secured asset-based revolving credit agreement with Wells Fargo Bank, National Association (“Revolving Facility”) that includes a $10,000 accordion feature under which the Revolving Facility may be expanded by agreement of the parties from up to $25,000 to up to $35,000 (in minimum increments of at least $5,000). Loans and other obligations under the Revolving Facility bear interest at a rate per annum equal to the daily Secured Overnight Financing Rate plus a margin of 2.00% or 2.25% depending on the monthly average excess availability under the Revolving Facility. The Credit Agreement requires that we comply with certain covenants, including that we (i) maintain at least $7,500 of liquidity at all times, and (ii) achieve certain minimum EBITDA thresholds specified in the Revolving Facility.
As of June 30, 2026, we had borrowings of $17,063 outstanding under the Revolving Facility. The outstanding borrowings as of June 30, 2026 were repaid to Wells Fargo in July 2026. The remaining borrowing capacity under the Revolving Facility was $7,531 as of June 30, 2026.
As of June 30, 2026, we were in compliance with all covenants under the Credit Agreement.
On June 26, 2026, in connection with our entry into the Revolving Facility, we repaid all outstanding borrowings under the WTI Loan Facility using proceeds from borrowings under the Revolving Facility, and terminated the WTI Loan Facility. We recognized a loss on extinguishment of $1,605 in connection with the extinguishment on the unaudited condensed consolidated statement of operations and comprehensive income (loss), of which $1,098 was due to the write-off of unamortized debt financing costs previously capitalized on the unaudited condensed consolidated balance sheets.
During the three months ended March 31, 2026, the WTI Funds sold to an unrelated third-party 310,000 shares of Owlet common stock previously classified in mezzanine equity due to the Redemption Option described in Note 4 within the Notes to Condensed Consolidated Financial Statements included elsewhere in this Report. As redemption rights are not transferable, we reclassified $2,439 of the mezzanine equity balance to Stockholders' Equity Additional Paid-In Capital upon sale.
As of March 31, 2026 principal outstanding on the loan was $6,259. The net carrying value of the WTI Loan Facility was $5,191, which includes the outstanding principal and accrued PIK interest of $291, net of $1,359 in unamortized debt financing costs.
As of March 31, 2026, we were in compliance with all covenants under the WTI Loan Facility.
On June 26, 2026, in connection with our entry into the Revolving Facility, we terminated the ABL Line of Credit. We recognized a loss on extinguishment of $604 in connection with the extinguishment on the unaudited condensed consolidated statement of operations and comprehensive income (loss), of which $374 was due to the write-off of unamortized loan commitment assets previously capitalized on the unaudited condensed consolidated balance sheets.
We, as guarantor, and our wholly-owned subsidiary, OBCI, as borrower, maintain an asset-based revolving credit facility (the “ABL Line of Credit”) with a maximum principal amount of up to $20,000 (the “Revolving Commitment”). The ABL Line of Credit is collateralized by substantially all of our assets.
As of March 31, 2026, there was $13,353 of outstanding borrowings under the ABL Line of Credit, and the remaining borrowing base availability was $3,944 as of March 31, 2026.
As of March 31, 2026, we were in compliance with all covenants under the Credit Agreement.
In 2025, wethe Company renewed a number of ourits insurance policies and entered into several new short-term commercial premium finance agreements with premium finance companies totaling $739 to be paid within one year, accruing interest at a weighted average rate of 8.0%.year. As of MarchJune 31,30, 2026, thethere was no remaining principal balance onoutstanding therelated combinedto financedthese insurance premiums was $224.agreements.
For the threesix months ended MarchJune 31,30, 2026, net cash used in operating activities was $5,049$5,141 as compared to net cash used in operating activities of $5,925$8,170 in the prior year. The positive change in operating cash flows was primarily driven by changesa significant improvement in net loss that was largely offset by an unfavorable swing in the non-cash fair value adjustment on our common stock warrant liability. The improvement also reflected positive impacts from a $2,209 loss on debt extinguishment related to the June 2026 debt refinancing and $3,589 higher stock-based compensation expense, partially offset by a net unfavorable change in operating assets and liabilities, particularlyprimarily relateddue to a smaller source of cash from accounts receivable, inventorypayable and accountsaccrued payable, as well as smaller common stock warrant liability adjustment compared to the prior year. These positive changes were partially offset by the $3,336 net loss recognized for the three months ended March 31, 2026, compared to the $3,025 net income recognized in the comparative prior year period.expenses.
For both the threesix months ended MarchJune 31,30, 2026 and MarchJune 31,30, 2025, we used $415$1,356 and $110$199 respectively, to invest in various projects, primarily for the development and enhancement of our new subscription app.
For the threesix months ended MarchJune 31,30, 2026 and MarchJune 31,30, 2025, net cash provided by financing activities was $5,462$2,034 and $2,014,$9,865, respectively. The increasedecrease is primarily driven by higher net proceeds from short-term borrowings in the currentrepayment periodof comparedlong-term borrowings, related to the priorJune period.2026 debt refinancing.
The One Big Beautiful Bill Act of 2025 (the “OBBBA”) was signed into law on July 4, 2025. The OBBBA makes changes to the U.S. corporate income tax, including reinstating the option to claim 100% accelerated depreciation deductions on qualified property, with retroactive application beginning January 20, 2025, and immediate expensing of domestic research and development costs, with retroactive application beginning January 1, 2025. The Company determined that the OBBBA did not have a material impact on the unaudited condensed consolidated financial statements for the three and six months ended MarchJune 31,30, 2026. The Act includes multiple effective dates, with certain provisions effective in 2026 and 2027. The Company will continue to evaluate the impact of these provisions on our 2026 and subsequent financial statements.
OWLT insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 3 filings (3 insiders, 14 trade dates, 90,688 shares, about $824.1K). Net open-market shares: -90,688 (purchases minus sales); net value about -$824.1K.Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
| Trade date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-08-12 | Stoll Marc F |
Grant/award | 26,785 | — | — |
| 2026-08-12 | Burke Zane M |
Grant/award | 26,785 | — | — |
| 2026-08-12 | Durr Laura |
Grant/award | 26,785 | — | — |
| 2026-08-12 | Gonzales Melissa |
Grant/award | 26,785 | — | — |
| 2026-08-12 | Kim John C. |
Grant/award | 26,785 | — | — |
| 2026-07-08 | Workman Kurt |
Shares withheld for tax | 21,001 | $5.91 | $124.1K |
| 2026-04-28 | Workman Kurt |
Grant/award | 850,000 | — | — |
| 2026-04-15 | Crawford Amanda |
Shares withheld for tax | 141 | $5.66 | $798 |
| 2026-02-27 | Crawford Amanda |
Open-market sale | 6,892 | $11.50 | $79.3K |
| 2026-02-26 | Harris Jonathan |
Open-market sale | 12,676 | $11.50 | $145.8K |
| 2026-02-26 | Harris Jonathan |
Grant/award | 41,666 | — | — |
| 2026-02-25 | Crawford Amanda |
Grant/award | 20,833 | — | — |
| 2026-02-17 | Harris Jonathan |
Open-market sale | 3,540 | $10.65 | $37.7K |
| 2025-11-17 | Harris Jonathan |
Open-market sale | 3,423 | $10.49 | $35.9K |
| 2025-10-16 | Stoll Marc F |
Grant/award | 18,996 | — | — |
| 2025-10-16 | Burke Zane M |
Grant/award | 18,996 | — | — |
| 2025-10-16 | Durr Laura |
Grant/award | 18,996 | — | — |
| 2025-10-16 | Gonzales Melissa |
Grant/award | 18,996 | — | — |
| 2025-10-16 | Kim John C. |
Grant/award | 18,996 | — | — |
| 2025-10-16 | Harris Jonathan |
Open-market sale | 1,851 | $8.75 | $16.2K |
| 2025-10-16 | Crawford Amanda |
Open-market sale | 149 | $8.75 | $1.3K |
| 2025-10-03 | Workman Kurt |
Open-market sale | 49,056 | $8.46 | $415.0K |
| 2025-09-30 | Harris Jonathan |
Grant/award | 60,024 | — | — |
| 2025-09-30 | Workman Kurt |
Grant/award | 14,098 | — | — |
| 2025-09-30 | Crawford Amanda |
Grant/award | 48,019 | — | — |
| 2025-09-17 | Workman Kurt |
Open-market sale | 1,014 | $7.25 | $7.4K |
| 2025-09-10 | Crawford Amanda |
Open-market sale | 4,225 | $7.06 | $29.8K |
| 2025-08-19 | Harris Jonathan |
Open-market sale | 3,315 | $7.72 | $25.6K |
| 2025-07-17 | Harris Jonathan |
Open-market sale | 1,945 | $8.03 | $15.6K |
| 2025-07-17 | Crawford Amanda |
Open-market sale | 157 | $8.03 | $1.3K |
| 2025-06-16 | Workman Kurt |
Open-market sale | 1,119 | $6.88 | $7.7K |
| 2025-04-16 | Crawford Amanda |
Open-market sale | 142 | $3.20 | $454 |
| 2025-03-18 | Workman Kurt |
Open-market sale | 1,044 | $4.26 | $4.4K |
| 2024-10-17 | Crawford Amanda |
Open-market sale | 140 | $4.92 | $689 |
Well-known investors holding OWLT (13F)
| Investor | Quarter | Shares | Reported value | % of their 13F | Change vs prior quarter |
|---|---|---|---|---|---|
| Citadel Advisors (Ken Griffin) | 2026-06-30 | 251,137 | $1.4M | 0.0% | New position |
| Renaissance Technologies | 2026-06-30 | 207,741 | $1.2M | 0.0% | Reduced 9% |
| Millennium Management (Israel Englander) | 2026-06-30 | 65,852 | $378.0K | 0.0% | Reduced 69% |